Our group recently reported that, in a phase 1 study, combination therapy of the nutlin compound RG7112 with doxorubicin potentiated p53 activation in a randomly selected patient population with advanced soft tissue sarcoma [35]. The gene discussed is TP53; the disease is soft tissue sarcoma.